Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL versus CLOXAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL versus CLOXAPEN.
BACTOCILL vs CLOXAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
None Documented
None Documented
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic